Jun 04, 2026 8:30am EDT RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd
May 28, 2026 8:30am EDT RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer
May 26, 2026 8:30am EDT RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting
May 19, 2026 8:30am EDT RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th
May 14, 2026 4:05pm EDT RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter
Apr 29, 2026 8:30am EDT RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET
Apr 23, 2026 8:30am EDT RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting
Apr 14, 2026 8:30am EDT Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting
Apr 08, 2026 8:30am EDT RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum
Apr 01, 2026 2:20pm EDT RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
